Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

229
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
229
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

267
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
267
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

439
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
439
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

202
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
202
Drug Therapy01:28

Drug Therapy

93
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
93
An Overview of Psychoactive Drugs01:28

An Overview of Psychoactive Drugs

284
Psychoactive drugs impact brain function, influencing perception, mood, consciousness, cognition, and behavior. These substances are grouped based on their effects and the mechanisms by which they act.
Stimulants such as cocaine, amphetamines, and nicotine enhance brain activity, leading to increased alertness, attention, and energy. These drugs typically raise heart rate, blood pressure, and body temperature. While they can induce feelings of euphoria, their misuse can result in severe health...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response-predictive MRI biomarkers of low-dose lithium therapy: cortical thickness changes in patients with bipolar depression.

Psychiatry research. Neuroimaging·2026
Same author

Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test.

European journal of pain (London, England)·2026
Same author

Artificial Intelligence-Empowered Multimodal Learning in Psychiatry: A Scoping Review.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2026
Same author

Plasma TREM2 levels, alcohol consumption, and liver enzymes in patients with alcohol use disorder: a sex-dependent relationship involving MS4A6A genetic polymorphism.

Journal of proteomics and genomics research·2026
Same author

Outreach Models for Substance Use Disorder in Homeless Populations: A Systematic Review and Network Meta-Analysis.

Psychiatric services (Washington, D.C.)·2026
Same author

Clinical and biological distinctions between catatonia due to a medical condition and catatonia associated with a psychiatric disorder.

General hospital psychiatry·2025

Related Experiment Video

Updated: Sep 4, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K

Psychedelic drugs for psychiatric disorders.

Sabrina Correa da Costa1, Tyler Oesterle2, Teresa A Rummans2

  • 1Department of Psychiatry and Psychology, Mayo Clinic Health System, La Crosse, WI, United States of America.

Journal of the Neurological Sciences
|July 16, 2022
PubMed
Summary

Psychedelic drugs like psilocybin, MDMA, and LSD show promise for treating psychiatric disorders, offering rapid benefits where traditional drugs fall short. Further research is needed to confirm long-term safety and efficacy for widespread clinical use.

Keywords:
HallucinogensLSDMDMA (ecstasy)PsilocybinPsychedelic-assisted psychotherapyPsychedelicsPsychiatric disorders

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.7K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Related Experiment Videos

Last Updated: Sep 4, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.7K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Current psychiatric treatments have limitations in efficacy, speed, and side effects.
  • Psychedelics have a long history of use and demonstrated potential in early research.
  • Renewed scientific interest in psychedelics is driven by the need for novel psychiatric treatments.

Purpose of the Study:

  • To provide an overview of current evidence for psychedelic drugs in psychiatric treatment.
  • To examine the potential of psilocybin, MDMA, and LSD for various mental health conditions.
  • To highlight the need for further research into the safety and efficacy of psychedelics.

Main Methods:

  • Review of existing scientific literature and clinical trial data.
  • Analysis of preliminary findings on the therapeutic effects of psychedelics.
  • Focus on specific compounds: psilocybin, MDMA, and LSD.

Main Results:

  • Psychedelics demonstrate rapid and sustained clinical benefits for psychiatric disorders.
  • Evidence suggests potential applications for alcohol use disorders, anxiety, and depression.
  • Preliminary findings are encouraging but require further investigation.

Conclusions:

  • Psychedelics show significant promise as novel psychiatric treatments.
  • More research is essential to establish long-term safety and efficacy.
  • Current evidence is insufficient for routine clinical adoption, pending ongoing trials.